Press Release
nChroma Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of Epigenetic Silencer CRMA-1001 for Chronic Hepatitis B
January 28, 2026
Press Release
nChroma Bio Receives Authorization of Clinical Trial Application to Initiate First-in-Human Study for Epigenetic Silencer CRMA 1001 for the Treatment of Chronic Hepatitis B
December 16, 2025
Press Release
nChroma Bio Presents Preclinical Data Demonstrating Epigenetic Silencing Approach as a Potential Functional Cure for Chronic Hepatitis B at AASLD 2025
November 7, 2025
Press Release
nChroma Bio Abstracts Accepted for The Liver Meeting® 2025 of the American Association for the Study of Liver Diseases (AASLD)
October 7, 2025
Resource
Integrated epigenetic and genetic programming of primary human T cells
September 9, 2025
Nature Biotechnology
Resource
Efficient and Liver-Detargeted In Vivo Multiplex Gene Editing of Human Hematopoietic Stem and Progenitor Cells
May 14, 2025
ASGCT Conference
Resource
Engineered Virus-Like Particles with Minimal Viral Components for Improved Base Editing Efficiency In Vivo
May 14, 2025
ASGCT Conference
Resource
E4/K4 Coiled-Coils Improve Cargo Loading in Engineered Virus-like Particles
May 14, 2025
ASGCT Conference
Resource
A novel PCSK9 Epigenetic Editor Achieves Maximal Pharmacology with Best-in-class Potency in Non-human Primates
May 4, 2025
EAS 93rd Congress
Press Release
nChroma Bio to Present at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting
April 28, 2025